These characteristics are intended to maximise the efficacy of the treatment and limit the inconvenience to the patient. PARI believes it has achieved these goals and made some other advances by launching Vios.
"We are excited for physicians treating respiratory diseases to begin prescribing Vios for patients. In addition to fast treatment times, patients will notice numerous enhancements to the Vios that are not included with other nebulizer systems”, added Geoff A. Hunziker, president of PARI.
Timestrip is one of the features that PARI believes differentiates Vios from other nebulizers. This is a time-sensitive indicator which reminds the patient to replace their nebulizer after six months.
PARI believes this replacement schedule helps maintain consistent medication delivery and fast treatment times, as well as reducing the risk of bacterial contamination, citing research published in the journal Respiratory Care to support its argument.
The technology consists of a Vios compressor and a PARI nebulizer. Physicians can choose between two nebulizers, PARI LC Plus and LC Sprint, to ensure that the product is suitable for a patient’s situation.
LC Plus has been marketed for more than 10 years and is capable of delivering over 65 per cent of the medicine in the respirable range. Furthermore, treatment times are six to seven minutes.
The LC Sprint model is the most recent addition to PARI’s range of nebulizers. It has been designed to speed delivery by up to 20 per cent, while maintaining the level of therapeutic in the respirable range, and also allows the user to see the level of medication left in the cup.